Expression and purification of the cancer antigen SSX2: A potential cancer vaccine

Protein Expression and Purification

Volumn 56, Issue 2, 2007, Pages 212-219

  Huang, Chung Jr ^a   Chen, Rishard H ^a   Vannelli, Todd ^a   Lee, Frank ^a   Ritter, Erika ^b   Ritter, Gerd ^b   Old, Lloyd J ^b   Batt, Carl A ^a  

^a Department of Obstetrics Gynecology   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Cancer testis antigen; Fermentation; Purification; SSX2; Vaccine

Indexed keywords

CANCER VACCINE; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; SYNOVIAL SARCOMA X BREAKPOINT PROTEINS; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; BIOSYNTHESIS; CONNECTIVE TISSUE TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; NEOPLASM; PLASMID; TIME;

ANTIGENS, NEOPLASM; CANCER VACCINES; CHROMATOGRAPHY, AFFINITY; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PLASMIDS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SARCOMA, SYNOVIAL; TIME FACTORS;

ESCHERICHIA COLI;

EID: 35448983175     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2007.07.009     Document Type: Article

References (29)

1. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G.R., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune-responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995) 11810-11813
2. Tureci O., Sahin U., Schobert I., Koslowski M., Schmitt H., Schild H.J., Stenner F., Seitz G., Rammensee H.G., and Pfreundschuh M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56 (1996) 4766-4772
3. Fligman I., Lonardo F., Jhanwar S.C., Gerald W.L., Woodruff J., and Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am. J. Pathol. 147 (1995) 1592-1599
4. + T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63 (2003) 5601-5606
5. + T cell responses in patients with hepatocellular carcinoma. J. Immunol. 174 (2005) 1709-1716
6. Scanlan M.J., Welt S., Gordon C.M., Chen Y.T., Gure A.O., Stockert E., Jungbluth A.A., Ritter G., Jager D., Jager E., Knuth A., and Old L.J. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62 (2002) 4041-4047
7. Neumann F., Wagner C., Stevanovic S., Kubuschok B., Schormann C., Mischo A., Ertan K., Schmidt W., and Pfreundschuh M. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int. J. Cancer 112 (2004) 661-668
8. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
9. Zendman A.J.W., Ruiter D.J., and Van Muijen G.N.P. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell Physiol. 194 (2003) 272-288
10. Gnjatic S., Nishikawa H., Jungbluth A.A., Gure A.O., Ritter G., Jager E., Chen Y.T., and Old L.J. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95 (2006) 1-30
11. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., Van der Bruggen P., and Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80 (1999) 219-230
12. Ayyoub M., Brehm M., Metthez G., Talbot S., Dutoit V., Taub R.N., Keohan M.L., Gure A.O., Chen Y.T., Williamson B., Jungbluth A.A., Old L.J., Hesdorffer C.S., and Valmori D. SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun. 3 (2003) 13
13. Stockert E., Jager E., Chen Y.T., Scalan M.J., Gout I., Karbach J., Arand M., Knuth A., and Old L.J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigen. J. Exp. Med. 187 (1998) 1349-1354
14. Ivanov A.V., Korovina A.N., Tunitskaya V.L., Kostyuk D.A., Rechinsky V.O., Kukhanova M.K., and Kochetkov S.N. Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expr. Purif. 48 (2006) 14-23
15. Choi A.H., Basu M., McNeal M.M., Bean J.A., Clements J.D., and Ward R.L. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. Protein Expr. Purif. 38 (2004) 205-216
16. Shiloach J., and Fass R. Growing E. coli to high cell density-a historical perspective on method development. Biotechnol. Adv. 23 (2005) 345-357
17. Faulkner E., Barrett M., Okor S., Kieran P., Casey E., Paradisi F., Engel P., and Glennon B. Use of fed-batch cultivation for achieving high cell densities for the pilot-scale production of a recombinant protein (phenylalanine dehydrogenase) in Escherichia coli. Biotechnol. Prog. 22 (2006) 889-897
18. Johnston W., Cord-Ruwisch R., and Cooney M.J. Industrial control of recombinant E. coli fed-batch culture: new perspectives on traditional controlled variables. Bioprocess Biosyst. Eng. 25 (2002) 111-120
19. Kim B.S., Lee S.C., Lee S.Y., Chang Y.K., and Chang H.N. High cell density fed-batch cultivation of Escherichia coli using exponential feeding combined with pH-stat. Bioprocess Biosys. Eng. 26 (2004) 147-150
20. Bailey S.M., and Meagher M.M. Separation of soluble protein from inclusion bodies in Escherichia coli lysate using crossflow microfiltration. J. Mem. Sci. 166 (2000) 137-146
21. Schoner R.G., Ellis L.F., and Schoner B.E. Isolation and purification of protein granules from Escherichia coli cells overproducing bovine growth hormone. Bio/Technology 3 (1985) 151-154
22. Hoare M., and Dunnill P. Biochemical engineering challenges of purifying useful proteins. Philos. Trans. R. Soc. Lond. B Biol. Sci. 324 (1989) 497-507
23. Mayer A., Sharma S.K., Tolner B., Minton N.P., Purdy D., Amlot P., Tharakan G., Begent R.H.J., and Chester K.A. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90 (2004) 2402-2410
24. Ye K.M., Jin S., Ataai M.M., Schultz J.S., and lbeh J. Tagging retrovirus vectors with a metal binding peptide and one step purification with a metal binding affinity chromatography. J. Virol. 78 (2004) 9820-9827
25. Takakura T., Ito T., Yagi S., Notsu Y., Itakura T., Nakamura T., Inagaki K., Esaki N., Hoffman R.M., and Takimoto A. High-level expression and bulk crystallization of recombinant l-methionine gamma-lyase, an anticancer agent. Appl. Microbiol. Biotechnol. 70 (2006) 183-192
26. Petsch D., and Anspach F.B. Endotoxin removal from protein solutions. J. Biotechnol. 76 (2000) 97-119
27. Wilson M.J., Haggart C.L., Gallagher S.P., and Walsh D. Removal of tightly bound endotoxin from biological products. J. Biotechnol. 88 (2001) 67-75
28. Shimp Jr. R.L., Martin L.B., Zhang Y., Henderson B.S., Duggan P., Macdonald N.J., Lebowitz J., Saul A., and Narum D.L. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 MSP1(42) in the absence of an affinity tag. Protein Expr. Purif. 50 (2006) 58-67
29. dos Santos N.R., Torensma R., de Vries T.J., Schreurs M.W., de Bruijn D.R., Kater-Baats E., Ruiter D.J., Adema G.J., van Muijen G.N., and van Kessel A.G. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 60 (2000) 1654-1662